Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Goldfinch Bio, Inc

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Gilead-partnered Goldfinch Bio lands $100M as it pivots to clinical stage biotech

              Contact the Supplier

              Lead Product(s): GFB-887

              Therapeutic Area: Nephrology Product Name: GFB-887

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eventide Asset Management

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Funding June 30, 2020

              Details:

              Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and will also support continued development of the Company’s discovery platform and preclinical pipeline.

              Aduro Biotech

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

              Contact the Supplier

              Lead Product(s): BION-1301

              Therapeutic Area: Nephrology Product Name: BION-1301

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 24, 2020

              Details:

              Part 3 of the Phase 1 multi-center trial is evaluating the safety and tolerability of BION-1301 in two cohorts of 20 total adult subjects with IgA nephropathy in an open-label multiple dose design.

              PharmaCompass__DigitalAd